SUMOylation modulates glucocorticoid-induced muscle toxicity in cell and mouse models
4 affiliations
- 1Research Institute of Korean Medicine, Pusan National University
- 2Department of Korean Medical Science, School of Korean Medicine, Pusan National University
- 3Department of Convergence Korean Medical Science, Graduate School of Pusan National University
- 4New Drug Development Center, Osong Medical Innovation Foundation
Abstract
Prolonged glucocorticoid (GC) exposure is a clinically relevant cause of skeletal muscle atrophy through activation of glucocorticoid receptor (GR)-dependent catabolic transcriptional programs, including those mediated by Krüppel-like factor 15 (KLF15). However, the post-translational regulatory mechanisms that modulate the magnitude of GC-driven catabolic signaling in skeletal muscle remain incompletely understood. In this study, we investigated the role of SUMOylation as a stress-responsive post-translational regulatory mechanism in GC-induced muscle toxicity. Pharmacological modulation of SUMOylation was examined using the SUMOylation activator N106 in differentiated C2C12 myotubes and in a DEX-treated mouse model, both subjected to dexamethasone (DEX) treatment. Morphological, transcriptional, and functional parameters were assessed in vitro and in vivo, and the requirement for SUMO conjugation was interrogated using the SUMO E1 inhibitor TAK981. DEX exposure was associated with reduced SUMO-conjugated protein levels and induced a robust GR-KLF15-dependent catabolic transcriptional response in skeletal muscle cells and tissues. Enhancement of SUMOylation by N106 attenuated DEX-induced reductions in myotube diameter and muscle fiber cross-sectional area and suppressed the induction of muscle atrogenes (Fbxo32, Trim63) and metabolic enzymes (Pdk4, Bcat2). In vivo, N106 mitigated DEX-associated impairments in muscle function, including grip strength and treadmill endurance. In contrast, pharmacological inhibition of SUMOylation by TAK981 enhanced GC-induced catabolic gene expression, supporting an important role for SUMO conjugation in regulating skeletal muscle stress responses. Collectively, these findings identify SUMOylation as a post-translational regulatory layer that constrains GR-mediated catabolic transcription under GC stress. Chemical modulation of the SUMOylation pathway influences the severity of GC-induced muscle atrophy, highlighting SUMOylation as an important determinant of skeletal muscle susceptibility to GC-induced toxicity.
Related
- Dysregulation of the MACF1‐Rab14/KIF16B‐FGFR Vesicular Trafficking Axis Skews MSC Lineage Commitment in Glucocorticoid‐Induced Osteoporosis
- Therapeutic potential of hydroxybenzoic acid and lentinan in mitigating glucocorticoid-induced osteoporosis: an experimental study
- Bazi Bushen Attenuates Skeletal Muscle Decline Associated With Oestrogen Deficiency and Modulates FGFR1/ERK Signalling.
- Salidroside ameliorates glucocorticoid-induced osteoporosis by regulating the PI3K/Akt/mTOR pathway: a network pharmacology and in vivo
- Prediction of Lindane-Induced Breast Cancer Toxicity Through Multi-Target Network Analysis and Mechanistic Investigation
BibTeX
@article{lee2026sumoylation,
title = {{SUMOylation modulates glucocorticoid-induced muscle toxicity in cell and mouse models}},
author = {Ahyoung Lee and Yoonhee Jeong and Hayeong Kwon and Myeongsu Kim and Seulmin Kim and Philyoung Lee and Changwon Kho},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-60353-9},
url = {https://doi.org/10.1038/s41598-026-60353-9},
note = {CC BY},
}
RIS
TY - JOUR
TI - SUMOylation modulates glucocorticoid-induced muscle toxicity in cell and mouse models
AU - Ahyoung Lee
AU - Yoonhee Jeong
AU - Hayeong Kwon
AU - Myeongsu Kim
AU - Seulmin Kim
AU - Philyoung Lee
AU - Changwon Kho
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-60353-9
UR - https://doi.org/10.1038/s41598-026-60353-9
AB - Prolonged glucocorticoid (GC) exposure is a clinically relevant cause of skeletal muscle atrophy through activation of glucocorticoid receptor (GR)-dependent catabolic transcriptional programs, including those mediated by Krüppel-like factor 15 (KLF15). However, the post-translational regulatory mechanisms that modulate the magnitude of GC-driven catabolic signaling in skeletal muscle remain incompletely understood. In this study, we investigated the role of SUMOylation as a stress-responsive post-translational regulatory mechanism in GC-induced muscle toxicity. Pharmacological modulation of SUMOylation was examined using the SUMOylation activator N106 in differentiated C2C12 myotubes and in a DEX-treated mouse model, both subjected to dexamethasone (DEX) treatment. Morphological, transcriptional, and functional parameters were assessed in vitro and in vivo, and the requirement for SUMO conjugation was interrogated using the SUMO E1 inhibitor TAK981. DEX exposure was associated with reduced SUMO-conjugated protein levels and induced a robust GR-KLF15-dependent catabolic transcriptional response in skeletal muscle cells and tissues. Enhancement of SUMOylation by N106 attenuated DEX-induced reductions in myotube diameter and muscle fiber cross-sectional area and suppressed the induction of muscle atrogenes (Fbxo32, Trim63) and metabolic enzymes (Pdk4, Bcat2). In vivo, N106 mitigated DEX-associated impairments in muscle function, including grip strength and treadmill endurance. In contrast, pharmacological inhibition of SUMOylation by TAK981 enhanced GC-induced catabolic gene expression, supporting an important role for SUMO conjugation in regulating skeletal muscle stress responses. Collectively, these findings identify SUMOylation as a post-translational regulatory layer that constrains GR-mediated catabolic transcription under GC stress. Chemical modulation of the SUMOylation pathway influences the severity of GC-induced muscle atrophy, highlighting SUMOylation as an important determinant of skeletal muscle susceptibility to GC-induced toxicity.
SN - 2045-2322
ER -